

## **Crafting a better T cell for immunotherapy**

February 22 2016



T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer. Now, a group of researchers led by Fred Hutchinson Cancer Research Center immunotherapy researcher Dr. Stanley Riddell has devised a new approach that could speed and improve this process, using a special, small protein tag that can be used to purify and track the T cells once they have been engineered in the laboratory. Credit: Fred Hutch News Service



T-cell therapy, a form of immunotherapy that uses a patient's own immune cells to attack their cancer, has been making waves recently. The "living" therapy involves engineering the patient's T cells in the laboratory to carry new proteins that guide the immune cells directly to tumor cells, allowing the engineered T cells to attack and kill the cancer.

Now, a group of researchers led by Fred Hutchinson Cancer Research Center immunotherapy researcher Dr. Stanley Riddell has devised a new approach that could speed and improve this process, using a special, small protein tag that can be used to purify and track the T cells once they have been engineered in the laboratory.

Riddell and his team describe the approach, and its effect on human <u>cancer</u> cells in the laboratory and on a mouse model of lymphoma, in a study publishing Monday in the journal *Nature Biotechnology*.

Although not yet tested in humans, the researchers believe this new approach could improve on current T-cell therapy methods in several ways:

- by boosting the cells' potency,
- by growing larger numbers of cancer-fighting T cells,
- by adding a potential "kill switch" to quickly deactivate the <u>cells</u> in patients' bodies in the event of toxic side effects and
- by cutting down the immune cell processing time from the current 14 to 20 days before reinfusion to 9 days or less.

Juno Therapeutics, a biotechnology company initially formed on technology from researchers at Fred Hutch, Memorial Sloan-Kettering Cancer Center and Seattle Children's Research Institute, has an exclusive license to the tag technology for uses related to oncology (as well as a



non-exclusive license for other purposes).

**More information:** Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy, <u>DOI: 10.1038/nbt.3461</u>

## Provided by Fred Hutchinson Cancer Research Center

Citation: Crafting a better T cell for immunotherapy (2016, February 22) retrieved 1 May 2024 from <u>https://medicalxpress.com/news/2016-02-crafting-cell-immunotherapy.html</u>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.